SARS-CoV-2 vaccine
- Generic Name
- SARS-CoV-2 vaccine
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
SARS-CoV-2 vaccine is an adjuvanted recombinant protein-based COVID-19 vaccine candidate being developed collaboratively by GlaxoSmithKline (GSK) and Sanofi. This vaccine candidate is composed of a spike protein antigen which aims to stimulate immune system production of antibodies against SARS-CoV-2; it uses technology previously employed for a recombinant ...
- Associated Conditions
- -
- Associated Therapies
- -
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 2450
- Registration Number
- NCT06694389
- Locations
- 🇯🇵
Fukuoka Heartnet Hospital, Fukuoka-shi, Fukuoka, Japan
🇯🇵Medical Coporation of Yamazaki Neurotology, Rhinolaryngology Clinical, Sapporo-shi, Hokkaido, Japan
🇯🇵Motomachi Takatsuka Naika Clinic - Internal Medicine, Yokohama-shi, Kanagawa, Japan
IMPACT OF KIDNEY FAILURE ON THE REGULATION OF HUMORAL RESPONSE TO VACCINATION
- Conditions
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-10-10
- Target Recruit Count
- 146
- Registration Number
- NCT06635525
- Locations
- 🇮🇹
ASST Santi Paolo e Carlo, Milano, Italy
🇮🇹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
🇮🇹ASST Fatebenefratelli Sacco, Milano, Italy
Vaccine Responses in Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-09-20
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 250
- Registration Number
- NCT06605625
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Humoral and Cellular Immunity Against SARS-COV-2 Vaccine in HIV-infected Patients Immunosuppressed
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Hospitales Universitarios Virgen del RocÃo
- Target Recruit Count
- 48
- Registration Number
- NCT05633927
- Locations
- 🇪🇸
Virgen del Rocio University Hospital, Sevilla, Spain
COVID-19 Vaccines Associated Malaise
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- University Hospital, Caen
- Target Recruit Count
- 1534706
- Registration Number
- NCT05234333
- Locations
- 🇫🇷
Caen University Hospital, Department of Pharmacology, Caen, Normandie, France
Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)
- Conditions
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT04747522
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.